A61K 47/6855
The tumour determinant being from breast cancer cell
Official title: {the tumour determinant being from breast cancer cell}
A61K47/6855 (The tumour determinant being from breast cancer cell) appears on 761 US grants and 1,533 published applications in this corpus.
Search patents in A61K- Granted patents
- 761
- Published applications
- 1,533
- Assignees
- 490
- Inventors
- 2,711
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 2 | 0 |
| 1990 | 1 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 1 | 0 |
| 1995 | 1 | 0 |
| 1996 | 2 | 0 |
| 1997 | 1 | 0 |
| 1998 | 1 | 0 |
| 1999 | 3 | 0 |
| 2000 | 1 | 0 |
| 2001 | 1 | 0 |
| 2002 | 1 | 3 |
| 2003 | 2 | 4 |
| 2004 | 1 | 7 |
| 2005 | 1 | 7 |
| 2006 | 5 | 8 |
| 2007 | 5 | 13 |
| 2008 | 3 | 21 |
| 2009 | 6 | 15 |
| 2010 | 4 | 15 |
| 2011 | 11 | 28 |
| 2012 | 10 | 27 |
| 2013 | 11 | 19 |
| 2014 | 19 | 62 |
| 2015 | 28 | 53 |
| 2016 | 47 | 99 |
| 2017 | 50 | 117 |
| 2018 | 56 | 94 |
| 2019 | 62 | 91 |
| 2020 | 65 | 101 |
| 2021 | 67 | 116 |
| 2022 | 46 | 107 |
| 2023 | 77 | 139 |
| 2024 | 73 | 137 |
| 2025 | 61 | 127 |
| 2026 | 36 | 123 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Bifunctional molecules for lysosomal targeting and related compositions and methods6 Oct 2026US 12,753,239 B2The Board of Trustees of the Leland Stanford Junior University
- Methods of treating residual breast cancer with trastuzumab emtansine22 Sep 2026US 12,740,962 B2Genentech, Inc.
- Diagnosis and treatment of cancer28 Jul 2026US 12,693,294 B2Rab Diagnostics AS
- Recombinant human sialidases, sialidase fusion proteins, and methods of using the same21 Jul 2026US 12,686,858 B2Palleon Pharmaceuticals Inc.
- Anti-HER2 immunoconjugates, and uses thereof14 Jul 2026US 12,678,513 B2Bolt Biotherapeutics, Inc.
- Delivery of dual payload of mmaf or mmae and tlr7 agonists8 Oct 2026US 2026/0306648 A1The Research Foundation for The State University of New York
- Conjugates comprising cleavable linkers8 Oct 2026US 2026/0306654 A1AstraZeneca AB
- Slc4a1 (band 3) binding single domain antibodies for increased blood retention8 Oct 2026US 2026/0308272 A1
- Systems and methods for targeted breast cancer therapies1 Oct 2026US 2026/0294809 A1American University of Sharjah
- Macrocyclic Drug Conjugate, and Preparation Method Therefor and Use Thereof1 Oct 2026US 2026/0295062 A1Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Most cited
By later US patents
- Monomethylvaline compounds capable of conjugation to ligands486US 7,498,298 B2Seattle Genetics, Inc. · 2009
- Compositions for targeting the vasculature of solid tumors254US 6,051,230 ABoard of Regents, The University of Texas System · 2000
- Methods of treatment using anti-ErbB antibody-maytansinoid conjugates152US 7,097,840 B2Genentech, Inc. · 2006
- Monomethylvaline compounds capable of conjugation to ligands152US 7,745,394 B2Seattle Genetics, Inc. · 2010
- Monomethylvaline compounds capable of conjugation to ligands148US 7,964,566 B2Seattle Genetics, Inc. · 2011